Champions Oncology (NASDAQ:CSBR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Friday, Zacks.com reports. The firm currently has a $13.00 price objective on the biotechnology company’s stock. Zacks Investment Research‘s target price would indicate a potential upside of 17.54% from the company’s current price.
According to Zacks, “Champions Oncology, Inc., formerly known as Champions Biotechnology, Inc., engages in the development of advanced technology solutions to personalize the development and use of oncology drugs. The Company’s Tumorgraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice followed by propagation of the resulting engraftments. This technology can evaluate tumor sensitivity/resistance to various single, combination standard and novel chemotherapy agents. Champions Oncology, Inc. is based in Baltimore, Maryland. “
Separately, Roth Capital lifted their target price on Champions Oncology from $13.50 to $16.00 and gave the stock a “buy” rating in a research report on Monday, March 22nd.
Champions Oncology (NASDAQ:CSBR) last released its earnings results on Thursday, March 11th. The biotechnology company reported $0.05 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.04. Champions Oncology had a negative return on equity of 29.93% and a negative net margin of 4.18%. The business had revenue of $10.81 million during the quarter, compared to the consensus estimate of $10.29 million. On average, research analysts anticipate that Champions Oncology will post 0.02 earnings per share for the current fiscal year.
Several hedge funds have recently added to or reduced their stakes in CSBR. Roubaix Capital LLC bought a new stake in shares of Champions Oncology in the fourth quarter valued at about $2,228,000. Millrace Asset Group Inc. grew its stake in Champions Oncology by 51.8% in the fourth quarter. Millrace Asset Group Inc. now owns 182,337 shares of the biotechnology company’s stock valued at $1,967,000 after purchasing an additional 62,228 shares during the last quarter. Strs Ohio grew its stake in Champions Oncology by 1,626.3% in the third quarter. Strs Ohio now owns 32,800 shares of the biotechnology company’s stock valued at $303,000 after purchasing an additional 30,900 shares during the last quarter. Squarepoint Ops LLC purchased a new position in Champions Oncology in the third quarter valued at about $152,000. Finally, BlackRock Inc. grew its stake in Champions Oncology by 3.4% in the fourth quarter. BlackRock Inc. now owns 465,459 shares of the biotechnology company’s stock valued at $5,023,000 after purchasing an additional 15,447 shares during the last quarter. Hedge funds and other institutional investors own 52.84% of the company’s stock.
Champions Oncology Company Profile
Champions Oncology, Inc develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.
Read More: What is a trade deficit?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.